New hope for hard-to-treat cancers: targeted combo shows promise

NCT ID NCT05194995

Ongoing Disease control Sponsor: Allist Pharmaceuticals, Inc. Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests a new drug (JAB-21822) combined with cetuximab in people with advanced colorectal, small intestine, or appendiceal cancers that have a specific KRAS G12C mutation. Participants must have already tried at least one standard treatment. The goal is to see if the combination is safe and can shrink tumors. This is not a cure, but aims to control the disease.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADVANCED COLORECTAL CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

appendiceal neoplasm appendix cancer colorectal cancer small intestine cancer small intestine carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ADVANCED COLORECTAL CANCER APPENDICEAL CANCER SMALL INTESTINAL CANCER

Contacts and locations

Locations

Research site01

Beijing, Beijing Municipality, 100101, China
Research site02

Beijing, Beijing Municipality, 100101, China
Research site05

Zhengzhou, Henan, 450000, China
Research site06

Harbin, Heilongjiang, 150000, China
Research site07

Zhengzhou, Henan, 450000, China
Research site08

Nanchang, Jiangxi, 330000, China
Research site09

Nanjing, Jiangsu, 210000, China
Research site11

Changsha, Hunan, 410000, China
Research site12

Beijing, Beijing Municipality, 100101, China
Research site13

Nanning, Guangxi, 530021, China
Research site16

Linyi, Shandong, 276002, China
Research site18

Wuhan, Hubei, 430079, China
Research site19

Hangzhou, Zhejiang, 310005, China
Research site23

Xi’an, Shanxi, 710000, China
Research site28

Shanghai, Shanghai Municipality, 200032, China
Research site29

Changsha, Hunan, 410000, China
Research site31

Beijing, Beijing Municipality, 100021, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.